Opexa Therapeutics has achieved its first technology transfer milestone in connection with its recently announced exclusive stem cell agreement with Novartis. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa. Opexa recently entered into an exclusive agreement with Novartis for the further development of its novel stem cell technology. Opexa received an upfront cash payment of $3 million and was entitled to an additional $1 million as a technology transfer fe...